Presentation10 Jun 2020 20:04
Once you register for tomorrow's sales pitch there's a Turner and pope document which makes great reading. Caveat is this is also a sales propaganda doc but I like this bit about our saliva test (they even have a dig at quidel):
the most efficient and simplest to use, early to market solution supported by comprehensive international distribution will likely capture the greatest slice of the commercial opportunity. Avacta appears positioned to secure this crown, having in addition also announced a collaboration with Adeptrix (Beverly, MA, USA) to develop and manufacture an Affimer®-based BAMS™ (bead-assisted mass spectrometry) coronavirus antigen test that will provide clinicians with a significant expansion of the available testing capacity for COVID-19 infection in hospitals. Presently there is only one other ‘nasal swab’ FDA-approved antigen test (from Quidel Corp), yet it appears to be somewhat flawed due to relatively (85%) poor detection sensitivity and is something which Avacta’s co-developed product is expected to surpass. From this point, timing is clearly key. There are presently only a few rapid antigen tests in development and, as yet, none have CE/FDA approval. In anticipation of quick development and subsequent approval, Avacta has already put in place one distribution partner, Medusa19, for the direct-to-consumer market and will put in place additional distribution partners for the healthcare professional/work-force testing markets, as well as OEM partnerships in order to maximise the commercial opportunity for the Affimer reagents it has developed that detect the coronavirus. Avacta intends to further commercialise the COVID-19 Affimer® reagents that it has generated through additional diagnostic development partnerships.
Sign In
Follow the stocks
